Clinical Trial Update: Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating bortezomib in patients with metastatic castration-resistant prostate cancer with PTEN deletion; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Bortezomib (bortezomib)

Snippet

Sponsor: University of Utah | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 2 | Status: RECRUITING